156 related articles for article (PubMed ID: 34699294)
1. Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic.
Javadinia SA; Ariamanesh M; Nabavifard M; Porouhan P; PeyroShabany B; Fazilat-Panah D; Hatami F; Ghasemi A; Lyman GH; Welsh JS; Ashkar Tizabi S; Dehghani M
Cancer Invest; 2022 Feb; 40(2):115-123. PubMed ID: 34699294
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
[TBL] [Abstract][Full Text] [Related]
3. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data.
Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Oliveros-Acebes E; García-Navarro MJ; Khosravi-Shahi P
Cancer Treat Rev; 2020 Nov; 90():102102. PubMed ID: 32947121
[TBL] [Abstract][Full Text] [Related]
5. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
Yazaki S; Yoshida T; Kojima Y; Yagishita S; Nakahama H; Okinaka K; Matsushita H; Shiotsuka M; Kobayashi O; Iwata S; Narita Y; Ohba A; Takahashi M; Iwasa S; Kobayashi K; Ohe Y; Yoshida T; Hamada A; Doi T; Yamamoto N
JAMA Oncol; 2021 Aug; 7(8):1141-1148. PubMed ID: 34047762
[TBL] [Abstract][Full Text] [Related]
6. High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-Sectional Population-Based Study.
Moreira-Soto A; Pachamora Diaz JM; González-Auza L; Merino Merino XJ; Schwalb A; Drosten C; Gotuzzo E; Talledo M; Arévalo Ramirez H; Peralta Delgado R; Bocanegra Vargas S; Drexler JF
mSphere; 2021 Dec; 6(6):e0068521. PubMed ID: 34817236
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study.
Spinelli MA; Lynch KL; Yun C; Glidden DV; Peluso MJ; Henrich TJ; Gandhi M; Brown LB
Lancet HIV; 2021 Jun; 8(6):e334-e341. PubMed ID: 33933189
[TBL] [Abstract][Full Text] [Related]
8. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
[TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
[TBL] [Abstract][Full Text] [Related]
10. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.
Iruretagoyena M; Vial MR; Spencer-Sandino M; Gaete P; Peters A; Delgado I; Perez I; Calderon C; Porte L; Legarraga P; Anderson A; Aguilera X; Vial P; Weitzel T; Munita JM
BMC Infect Dis; 2021 May; 21(1):478. PubMed ID: 34039287
[TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.
Kataria Y; Cole M; Duffy E; de la Cena K; Schechter-Perkins EM; Bouton TC; Werler MM; Pierre C; Ragan EJ; Weber SE; Jacobson KR; Andry C
Sci Rep; 2021 May; 11(1):9694. PubMed ID: 33958668
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
[TBL] [Abstract][Full Text] [Related]
14. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
[TBL] [Abstract][Full Text] [Related]
16. Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003.
Tseng WP; Wu JL; Wu CC; Kuo KT; Lin CH; Chung MY; Lee YF; Yang BJ; Huang CH; Chen SY; Yu CJ; Chen SC; Hsueh PR
Front Immunol; 2021; 12():626609. PubMed ID: 34084161
[TBL] [Abstract][Full Text] [Related]
17. Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study.
Brehm TT; Schwinge D; Lampalzer S; Schlicker V; Küchen J; Thompson M; Ullrich F; Huber S; Schmiedel S; Addo MM; Lütgehetmann M; Knobloch JK; Schulze Zur Wiesch J; Lohse AW
Int J Hyg Environ Health; 2021 Mar; 232():113671. PubMed ID: 33338782
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
[TBL] [Abstract][Full Text] [Related]
19. SARS-COV-2 IgG antibody response in pregnant women at delivery.
Tsatsaris V; Mariaggi AA; Launay O; Couffignal C; Rousseau J; Ancel PY; Marcault E; Ville Y; Cordier AG; Vivanti A; Carrara J; Luton D; Dommergues M; Borie C; Kayem G; Alessandrini V; Lecomte L; Meritet JF; Leruez-Ville M; Goffinet F; Dubois C; Picone O; Vauloup Fellous C
J Gynecol Obstet Hum Reprod; 2021 Sep; 50(7):102041. PubMed ID: 33310133
[TBL] [Abstract][Full Text] [Related]
20. Detection of SARS-CoV-2 antibodies in pediatric patients: An Iranian referral hospital-based study.
Mamishi S; Esslami GG; Mohammadi M; Abdolsalehi MR; Sadeghi RH; Mahmoudi S; Pourakbari B
Hum Antibodies; 2021; 29(3):217-223. PubMed ID: 34151783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
